{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:33:48Z","timestamp":1787099628627,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/leu.2017.214","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T05:59:48Z","timestamp":1499234388000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy"],"prefix":"10.1038","volume":"32","author":[{"given":"M O","family":"Holmstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Martinenaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-4969","authenticated-orcid":false,"given":"P","family":"thor Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I M","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H C","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"BFleu2017214_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD . Cancer immunoediting: from immuno- surveillance to tumor escape. Nat Immunol 2002; 3: 991\u2013998.","journal-title":"Nat Immunol"},{"key":"BFleu2017214_CR2","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"F Olivera","year":"2008","unstructured":"Olivera F . Cancer Immunology. N Engl J Med 2008; 358: 2704\u20132715.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T . Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135\u2013146.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017214_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD . Neoantigens in cancer immunotherapy. Science 2015; 348: 69\u201374.","journal-title":"Science"},{"key":"BFleu2017214_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452\u20132466.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779\u20131790.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","volume":"30","author":"MO Holmstrom","year":"2016","unstructured":"Holmstrom MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH . The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 2016; 30: 2413\u20132416.","journal-title":"Leukemia"},{"key":"BFleu2017214_CR10","first-page":"178","volume-title":"Cell Biology: A Laboratory Handbook, 2nd edn","author":"R Packer","year":"1998","unstructured":"Packer R, Bolton B Immortalization of B lymphocytes by Epstein Barr virus. In: Celis JE (ed) Cell Biology: A Laboratory Handbook, 2nd edn. Academic Press: San Diego, CA, USA, 1998; pp 178\u2013185."},{"key":"BFleu2017214_CR11","first-page":"1","volume":"30","author":"D Pietra","year":"2015","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2015; 30: 1\u20138.","journal-title":"Leukemia"},{"key":"BFleu2017214_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, L\u00f6wer M et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59: 1489\u20131501.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu2017214_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1084\/jem.20150519","volume":"213","author":"A Takeuchi","year":"2016","unstructured":"Takeuchi A, MESG Badr, Miyauchi K, Ishihara C, Onishi R, Guo Z et al. CRTAM determines the CD4+cytotoxic T lymphocyte lineage. J Exp Med 2016; 213: 123\u2013138.","journal-title":"J Exp Med"},{"key":"BFleu2017214_CR14","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346\u20135354.","journal-title":"Blood"},{"key":"BFleu2017214_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/ehm.12.71","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver RT, Kiladjian J-J, Hasselbalch HC . Interferon and the treatment of polycythaemia vera, essential thrombocytemia and myelofibrosis. Exp Hematol 2013; 6: 1\u201310.","journal-title":"Exp Hematol"},{"key":"BFleu2017214_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1401255","volume":"371","author":"B Cassinat","year":"2014","unstructured":"Cassinat B, Verger E, Kiladjian J-J . Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014; 371: 188\u2013189.","journal-title":"N Engl J Med"},{"key":"BFleu2017214_CR17","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Dosquet C, Giraudier S . Clinical and molecular response to interferon- a therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; 126: 2585\u20132592.","journal-title":"Blood"},{"key":"BFleu2017214_CR18","doi-asserted-by":"publisher","first-page":"e0165336","DOI":"10.1371\/journal.pone.0165336","volume":"11","author":"L Kj\u00e6r","year":"2016","unstructured":"Kj\u00e6r L, Cordua S, Holmstr\u00f6m MO, Thomassen M, Kruse TA, Pallisgaard N et al. Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment. PLoS ONE 2016; 11: e0165336.","journal-title":"PLoS ONE"},{"key":"BFleu2017214_CR19","first-page":"1","volume":"30","author":"J-J Kiladjian","year":"2015","unstructured":"Kiladjian J-J, Giraudier S, Cassinat B . Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 2015; 30: 1\u20136.","journal-title":"Leukemia"},{"key":"BFleu2017214_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12687","volume":"97","author":"CH Riley","year":"2016","unstructured":"Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L et al. Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol 2016; 97: 83\u201392.","journal-title":"Eur J Haematol"},{"key":"BFleu2017214_CR21","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","volume":"118","author":"CH Riley","year":"2011","unstructured":"Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-\u03b1. Blood 2011; 118: 2170\u20132173.","journal-title":"Blood"},{"key":"BFleu2017214_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.12420","volume":"94","author":"CH Riley","year":"2015","unstructured":"Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT et al. Expansion of circulating CD56(bright) natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1. Eur J Haematol 2015; 94: 227\u2013234.","journal-title":"Eur J Haematol"},{"key":"BFleu2017214_CR23","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","volume":"54","author":"V Skov","year":"2013","unstructured":"Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013; 54: 2269\u20132273.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017214_CR24","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","volume":"58","author":"V Skov","year":"2017","unstructured":"Skov V, Riley CH, Thomassen M, Kj\u00e6r L, Stauffer Larsen T, Bjerrum OW et al. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leuk Lymphoma 2017; 58: 1914\u20131921.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017214_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00531","volume":"7","author":"Y Tian","year":"2016","unstructured":"Tian Y, Sette A, Weiskopf D . Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection. Front Immunol 2016; 7: 1\u20139.","journal-title":"Front Immunol"},{"key":"BFleu2017214_CR26","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.4049\/jimmunol.163.7.3812","volume":"163","author":"MH Andersen","year":"1999","unstructured":"Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999; 163: 3812\u20133818.","journal-title":"J Immunol"},{"key":"BFleu2017214_CR27","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","volume":"127","author":"I Chachoua","year":"2016","unstructured":"Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016; 127: 1325\u20131335.","journal-title":"Blood"},{"key":"BFleu2017214_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54\u201361.","journal-title":"Nat Med"},{"key":"BFleu2017214_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","volume":"43","author":"JC Wang","year":"2016","unstructured":"Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C . Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res 2016; 43: 39\u201343.","journal-title":"Leuk Res"},{"key":"BFleu2017214_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","volume":"158","author":"M Munder","year":"2009","unstructured":"Munder M . Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009; 158: 638\u2013651.","journal-title":"Br J Pharmacol"},{"key":"BFleu2017214_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA . Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016; 375: 1767\u20131778.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017214","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:06:16Z","timestamp":1692853576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFleu2017214"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.214","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727777578.793564983","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"assertion":[{"value":"22 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. However, it should be noted that Morten Orebo Holmstr\u00f6m, Hans Carl Hasselbalch and Mads Hald Andersen have filed a patent regarding the\n                      CALR\n                      exon 9 mutations as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region, and Copenhagen University Hospital at Herlev, Capital Region, according to Danish Law concerning inventions made at public research institutions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}